MENU
Aim higher

OptiFemVac

Cost-effective Vaccines for Female Reproductive and Infant Health

We aim to develop vaccines targeting female reproductive and infant health, enhanced by delivery platforms designed to produce and deliver efficacious vaccines more cost effectively. The platforms allow optimal display of multiple antigens in one vaccine unit to evoke strong and long-lasting antibody and cellular responses. The main focus will be a Zika vaccine, with additional preclinical data for a combined Human Papilloma Virus (HPV) and Placental Malaria (PM) vaccine.
Acronym: 
OptiFemVac
Project ID: 
11 019
Ranking: 
33
Cut-off: 
6
Start date: 
01-04-2017
Project Duration: 
36months
Project costs: 
1 600 290.00€
Technological Area: 
Virus, Virology, Vaccines/ Antiobiotics / Bacteriology
Market Area: 
Pharmaceuticals/fine chemicals